Business Description
Bicara Therapeutics Inc. is a Boston-based medical research company focused on developing new treatments for solid tumor cancers. Founded in 2018, the company is advancing ficerafusp alfa, its primary drug candidate, which works by targeting two key biological pathways involved in tumor growth at the same time. This dual-action approach is designed to improve on existing cancer therapies and offer better outcomes for patients.